08:00 , Dec 22, 2014 |  BC Week In Review  |  Financial News

PlasmaTech Biopharmaceuticals completes follow-on

PlasmaTech Biopharmaceuticals Inc. (NASDAQ:PTBI), Dallas, Texas   Business: Cancer, Drug delivery   Date completed: 2014-12-18   Type: Follow-on   Raised: $14 million   Shares: 3.5 million   Price: $4   Shares after offering: 4 million   Underwriters: H.C. Wainwright; Aegis Capital   Overallotment: 525,000...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Company News

Access Pharmaceuticals, Norgine deal

PlasmaTech (formerly Access Pharmaceuticals Inc.) and Norgine added Australia and New Zealand to an August deal granting Norgine an exclusive license to commercialize, develop and manufacture MuGard in the EU, Switzerland, Norway, Iceland and...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Financial News

PlasmaTech Biopharmaceuticals financial update

PlasmaTech Biopharmaceuticals Inc. (OTCQB:ACCPD), Dallas, Texas   Business: Cancer, Drug delivery   Date announced: 2014-10-24   Note: PlasmaTech (formerly Access Pharmaceuticals Inc.) implemented a 1-for-50 reverse stock split and began trading under the ticker "ACCPD." Following the...
07:00 , Sep 8, 2014 |  BC Week In Review  |  Company News

Access Pharmaceuticals, Norgine deal

Access granted Norgine exclusive rights to develop and commercialize Access' MuGard for oral mucositis in the EU, Switzerland, Norway, Iceland and Lichtenstein. Access is eligible for up to $10 million in milestones, plus escalating...
07:00 , Jul 14, 2014 |  BC Week In Review  |  Financial News

Access Pharmaceuticals Inc proposes follow-on

Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas   Business: Cancer, Drug delivery   Date announced: 2014-07-02   Type: Follow-on   To be raised: Up to $23 million   Shares: TBD   Price prior: $0.30   Underwriter: Aegis Capital   ...
07:00 , Mar 17, 2014 |  BC Week In Review  |  Company News

Access Pharmaceuticals, Hanmi Pharmaceutical sales and marketing update

Access granted Hanmi exclusive rights to commercialize MuGard in South Korea. Access will receive an undisclosed upfront payment and is eligible to receive double-digit royalties on net sales. The mucoadhesive oral rinse has been...
08:00 , Mar 3, 2014 |  BC Week In Review  |  Clinical News

MuGard: Phase IV data

Data from 78 evaluable head and neck cancer patients receiving chemoradiation therapy in a double-blind, U.S. Phase IV trial showed that oral MuGard significantly reduced area under the curve of daily patient-reported OMDQ scores, the...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Access Pharmaceuticals, AMAG Pharmaceuticals sales and marketing update

AMAG licensed exclusive, U.S. commercialization rights to MuGard mucoadhesive oral rinse from Access for an upfront payment of $3.3 million. Access is also eligible for a tiered, double-digit royalty on net sales of MuGard....
07:00 , Oct 29, 2012 |  BC Week In Review  |  Financial News

Access Pharmaceuticals completes private placement of units

Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas   Business: Cancer, Drug delivery   Date completed: 10/25/12   Type: Private placement of units   Raised: $4.7 million   Units: 20 million   Price: $0.50 (unit)   Shares outstanding prior: 24.2 million   Investors: Existing investors...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

MuGard: Interim Phase IV data

Interim data from 40 patients receiving chemoradiation therapy in a double-blind, U.S. Phase IV trial showed that oral MuGard significantly reduced mouth and throat soreness vs. an aqueous control rinse. MuGard also reduced the use...